It's been a banner year so far for Insmed Inc. (INSM), with its shares having more than doubled, thanks to Arikayce's surging sales, Brensocatib's ASPEN study success, and TPIP's promising phase II results.
Arikayce, the company's marketed drug, is an antibacterial drug, which secured accelerated approval from the FDA in Sep.2018, for the treatment of a serious lung disease caused by a group of bacteria, Mycobacterium avium complex, in adults who have limited or no alternative treatment options.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com